DADA (diisopropylamine dichloroacetate) is the diisopropylamine salt of dichloroacetic acid.
Amounts reported for DADA are listed under Reported protocols, each with its source and study kind. No amount ladder is inferred from them. This is educational source context, not a protocol or recommendation.
Enter a target amount only from your own reviewed source. The calculator can convert it into concentration, volume and device markings, but it will not infer an amount from product availability or another compound.
Only mcg or mg amounts are retained. The calculator derives mL, syringe units or pen clicks from the current vial strength, water volume and device.
Human study rows are described per source under Reported protocols; they belong to their trial populations and are not a general amount.
Verify the exact compound, formulation and amount against the product label or certificate before calculation.
Follow the product label, certificate and validated laboratory SOP; no universal storage assumption is applied here.
Label concentration and preparation date, use sterile technique where applicable, and follow a validated stability protocol.
What published studies and recent community write-ups report about amounts, timing and course length. 1 clinical, 2 preclinical and 1 community-reported rows, each linked to its source. These are descriptions of what others report, not instructions, and nothing here is medical advice.
| Context | Dose | Frequency | Route | Course | Source |
|---|---|---|---|---|---|
| Clinical1 row | |||||
| Japanese prescribing information (Liverall tablets and powder)Adults with chronic liver disease, for improvement of liver function | 20-60 mg per day, adjusted by age and symptoms | Divided into 2 or 3 doses a day | Oral: 20 mg tablets or a 10% powder | Not fixed by the labelNot described | Pharmaceuticals and Medical Devices Agency, Japan2026 |
| The package insert filed with Japan's Pharmaceuticals and Medical Devices Agency gives this as the only approved human regimen, notes that no paediatric trials were run and that older patients may need a lower dose, and describes the mechanism as promoting hepatic nucleic acid synthesis and liver regeneration in animal studies. The product is a Japanese prescription medicine; it has no marketing authorisation in the United States or Europe. | |||||
| Preclinical2 rows | |||||
| Mouse model of severe influenza4-week-old female C57BL/6 mice infected intranasally with influenza A PR/8/34 (H1N1) | 50 mg/kg per dose | Every 12 hours | Oral, in a methylcellulose suspension | 14 days, starting immediately after infectionNot applicable | PLoS One (PubMed)2014 |
| Infection suppressed pyruvate dehydrogenase activity and ATP levels in muscle, heart, liver and lung; DADA restored both, corrected blood glucose and lipid disturbances and markedly improved survival. The dose was chosen to match the molar range of dichloroacetate used clinically (25-100 mg/kg per day). Two authors were employees of Daiichi Sankyo Healthcare, which supplied the compound, and the authors hold a patent application on DADA for influenza. | |||||
| Mouse breast tumour transplant modelMice carrying subcutaneous MDA-MB-231 human breast adenocarcinoma transplants | 100 mg/kg | Not stated | Not stated | 24 daysNot applicable | Oncotarget (PubMed)2016 |
| At the same 100 mg/kg dose, DADA suppressed tumour growth better than dichloroacetate, with tumour necrosis, inflammation and fibrosis on histology and less Ki67 staining. In culture its half-maximal inhibitory concentration against the same cells was 7.1 mmol/L against 15.6 mmol/L for dichloroacetate, and it reduced lactate production and glucose uptake at 10 mmol/L. These are millimolar concentrations in cell culture and a xenograft model, not evidence of an effect in people. | |||||
| Community-reported1 row | |||||
| Vendor capsule listing | 200 mg per capsule | Not stated | Oral capsule | Not stated | Community resource2026 |
| This is a vendor claim: the vendor sells DADA as 200 mg GMP capsules for metabolic pathway research and states no dosing. A single capsule holds more than three times the top of the Japanese label's 20-60 mg daily range, and the vendor's research guide describes the product only as a capsule format for laboratory workflows. | |||||
Plus 1 community resource (a dosing guide, forum thread or vendor write-up), reported above but not linked.
DADA (diisopropylamine dichloroacetate) is the diisopropylamine salt of dichloroacetic acid, an oral small molecule sold in Japan as Liverall for improving liver function in chronic liver disease. It is studied as an inhibitor of pyruvate dehydrogenase kinase, the enzyme that steers cells away from burning glucose in their mitochondria, and recent preclinical work has tested it in mouse models of severe influenza, breast cancer and lung cancer. It is not approved in the United States or Europe, and the Japanese label is the only human dosing on record.
These themes describe recurring questions in published research. They are not claims of effectiveness or recommendations for use.
Energy balance, body composition and incretin signaling.
The package insert filed with Japan's Pharmaceuticals and Medical Devices Agency gives this as the only approved human regimen, notes that no paediatric trials were run and that older patients may need a lower dose.
Infection suppressed pyruvate dehydrogenase activity and ATP levels in muscle, heart, liver and lung; DADA restored both, corrected blood glucose and lipid disturbances and markedly improved survival. The dose was.
At the same 100 mg/kg dose, DADA suppressed tumour growth better than dichloroacetate, with tumour necrosis, inflammation and fibrosis on histology and less Ki67 staining. In culture its half-maximal inhibitory.
This is a vendor claim: the vendor sells DADA as 200 mg GMP capsules for metabolic pathway research and states no dosing. A single capsule holds more than three times the top of the Japanese label's 20-60 mg daily.
Study models remain visible so laboratory and animal findings are not mistaken for established human outcomes.
1 protocol row on this page come from human trials, trial registrations, regulator labels or reviews of human data. Approval status and populations are stated per row.
2 protocol rows describe animal, cell or toxicology work. Amounts from these rows do not translate to people.
1 row record what blogs, vendor write-ups or forums describe for DADA. None has been verified against primary literature.
Sequence, synonyms and registry identifiers as recorded in PubChem, the National Library of Medicine's open chemistry database. Formula, mass and CAS number are summarized at the top of the page.
Diisopropylamine dichloroacetate, Diisopropylammonium dichloroacetate, DADA, Liverall, DIPA-DCA, Dipromonium, IS-401, UNII BA6QDP0R4E
ILKBHIBYKSHTKQ-UHFFFAOYSA-N
2,2-dichloroacetic acid;N-propan-2-ylpropan-2-amine
6 curated references, each with its journal, year and study model, plus 1 community resource reported but not linked.